Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IPI-145

Phase 2Small molecule

IPI-145 is one of 31 small molecule programs targeting Phase 1. It is currently in Phase 2.

1

Indications

13

Total Trials

1

Active Trials

30

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase 1Active, not recruiting

Phase 1Phase 2

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Phase 1

#DrugCompanyPhaseTrials

Rituxan

Fludara

Venclexta

Cytoxan

BBaxter Healthcare Corporation

Erbitux

Rayos

RRoxane Laboratories

Navitoclax

Yervoy

Bristol-Myers Squibb

Benznidazole

CCorestemchemon, Inc.

VX-407

Vertex Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phase 12 trials

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Active, not recruiting·—·Phase 1/2·NCT02158091·32 enrolled

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

Completed·SSecuraBio·Phase 1·NCT01947777·14 enrolled

CLL/SLL2 trials

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Completed·SSecuraBio·Phase 3·NCT02049515·99 enrolled

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Terminated·SSecuraBio·Phase 1·NCT02292225·3 enrolled

Tics1 trial

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Completed·SSecuraBio·Phase 1·NCT02307461·103 enrolled

Hematologic Malignancies1 trial

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT01871675·48 enrolled

Advanced Hematologic Malignancies1 trial

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Terminated·SSecuraBio·Phase 1·NCT01476657·210 enrolled

6 more indications

MPA1 trial

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

Completed·SSecuraBio·Phase 1·NCT02095587·24 enrolled

Rheumatoid Arthritis1 trial

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

Completed·SSecuraBio·Phase 2·NCT01851707·322 enrolled

Midazolam1 trial

Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam

Completed·SSecuraBio·Phase 1·NCT01925911·14 enrolled

DME1 trial

IPI-145 ADME and Absolute Bioavailability Study

Completed·SSecuraBio·Phase 1·NCT01836861·6 enrolled

Interaction1 trial

IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study

Completed·SSecuraBio·Phase 1·NCT01549106·106 enrolled

Acute Lymphoblastic Leukemia1 trial

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02028039

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for IPI-145. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPI-145 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPI-145. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SecuraBio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecuraBio

Related News